We’ve updated our Privacy Policy in accordance with changes to data protection laws. If you’d like to read our Privacy Policy, please click here.
PEBEQ is the first validated test to be developed in the United States and follow the FDA guidelines.
It’s the most common sexual dysfunction affecting some 25 million men. Most studies evaluating treatments for PE include IELT in the definition of PE.
It has been estimated that PE affects 30-40% of the male population, but is paradoxically a condition for which they are least likely to seek help.
Reading AE, Weist WM. An analysis of self-reported sexual behavior in a sample of normal males. Arch Sex Behav. 1984;13(1):69-83.The International Society for Sexual Medicine (ISSM) developed the first evidence-based definition of PE. This definition, published in 2008, was initially limited to men with lifelong PE who engage in vaginal sexual intercourse:
“A male sexual dysfunction characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy”. Mc Mahon CG, Althof SE, Waldinger MD et al, An evidence-based unified definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) ad hoc committee for the definition of premature ejaculation. J Sex Med. 2008;5(7):1590-606.Behavioral therapy has been commonly used to treat PE, though with limited success; most post-therapy benefits are lost within three years of treatment Systemic treatments have included adrenergic antagonists, gamma-amino butyric acid (GABA) and selective serotonin reuptake inhibitors (SSRIs). Success with these agents has been variable and is associated with side effects.
De Amicis LA, Goldberg DC, LoPiccolo J, Friedman J, Davies L. Clinical follow-up of couples treated for sexual dysfunction. Arch Sex Behav. 1985;14(6):467-89.Yes. Plethora Solutions is developing a new therapy to treat PE. Plethora Solutions has established clinical information that a favorable benefit risk ratio and late phase studies are ongoing now.
